Новый подход к выбору гормональной контрацепции через систематизацию существующих препаратов

1. World Contraceptive Use 2003. United Nations Department of Economic and Social Affairs Population Division.

2. Статистическая информация Минздрава России. Available at: https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskaya-informatsiya-minzdrava-rossii

3. Прилепская В.Н., ред. Руководство по контрацепции. М.: МЕДпресс-информ; 2010. 448с.

4. Armstrong C. ACOG Guidelines on noncontraceptive uses of hormonal contraceptives. Am. Fam. Physician. 2010; 82(3): 288-95.

5. Wiegratz I., Kuhl H. Metabolic and clinical effects of progestogens. Eur. J. Contracept. Reprod. Health Care. 2006; 11(3): 153-61.

6. Blanc A.K., Curtis S., Croft T. Does contraceptive discontinuation matter? Quality of care and fertility consequences. MEASURE Evaluation Technical Report Series No. 3. Carolina Population Center, University of North Carolina at Chapel Hill; 1999.

7. Volumetric concept test. Ipsos, 2014.

8. Usage & Attitude, GFK, 2012.

9. Akerlund M., Røde A., Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br. J. Obstet. Gynaecol. 1993; 100(9): 832-8.

10. Endrikat J.S., Milchev N.P., Kapamadzija A., Georgievska J., Gerlinger C., Schmidt W., Feroze S. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception. 2009; 79(6): 428-32.

11. Дубровина С.О. Синдром поликистозных яичников: современный обзор. Гинекология. 2016; 18(5): 14-9.

12. Ткаченко Л.В., Свиридова Н.И. Гиперпластические процессы эндометрия в пременопаузе: современные возможности гормональной коррекции и профилактики. Гинекология. 2013; 15(2): 8-12.

13. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008; 61(1-2): 151-7.

14. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2): CD006586.

15. Lucky A.W., Koltun W., Thiboutot D., Niknian M., Sampson-Landers C., Korner P., Marr J. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008; 82(2): 143-50.

16. Niemeier V., Kupfer J., Gieler U. Acne vulgaris--psychosomatic aspects. J. Dtsch. Dermatol. Ges. 2006; 4(12): 1027-36.

17. Jones-Caballero M., Chren M.M., Soler B., Pedrosa E., Peñas P.F. Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment. J. Eur. Acad. Dermatol. Venereol. 2007; 21(2): 219-26.

18. Aydinlik S., Kaufmann J., Lachnit-Fixson U., Lehnert J. Long-term therapy of signs of androgenisation with a low-dosed antiandrogen-oestrogen combination. Clin. Trials J. 1990; 27(6): 392-402.

19. Национальные медицинские критерии приемлемости методов контрацепции. М.; 2012.

20. WHO. Medical eligibility criteria for contraceptive use. 5th ed. 2015. 267p.

21. Здравоохранение в России 2015. Статистический сборник/Росстат. М.; 2015. 174с.

22. Korver T. et al. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. Eur. J. Contracept. Reprod. Health Care. 1998; 3(4): 169-78.

Поступила 16.12.2016

Принята в печать 23.12.2016